Pharmacokinetics of beta-lactam antibiotics in patients with intra-abdominal disease: A structured review

Surgical Infections

Volumn 13, Issue 1, 2012, Pages 9-17

  Adnan, Syamhanin ^a,b   Paterson, David L ^b,c   Lipman, Jeffrey ^a,c   Kumar, Suresh ^e   Li, Janice ^a   Rudd, Michael ^a,c   Roberts, Jason A ^a,c,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^e HOSPITAL SUNGAI BULOH   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; BIAPENEM; CARBAPENEM; CEFEPIME; CEFOTIAM; CEFOZOPRAN; CEFTAZIDIME; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; DORIPENEM; ERTAPENEM; MEROPENEM; MONOBACTAM; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ABDOMINAL SURGERY; ABSCESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; INTESTINE ISCHEMIA; INTESTINE PERFORATION; INTRAABDOMINAL HYPERTENSION; LAPAROTOMY; PERITONITIS; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; SURGICAL DRAINAGE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CARBAPENEMS; CEPHALOSPORINS; DIFFUSION; DRAINAGE; HUMANS; INTRAABDOMINAL INFECTIONS; METABOLIC CLEARANCE RATE; PENICILLINS;

EID: 84863278700     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2011.046     Document Type: Review

References (66)

1. Linde-Zwirble WT, Angus DC. Severe sepsis epidemiology: Sampling, selection, and society. Crit Care 2004;8:222-226. (Pubitemid 39144709)
2. Boussekey N, Cantrel J, Dorchin Debrabant L, et al. Epidemiology, prognosis, and evolution of management of septic shock in a French intensive care unit: A five years survey. Crit Care Res Pract 2010;436427 E pub 2010 Jun 17.
3. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect 2010;11:79-109.
4. Swenson BR, Metzger R, Hedrick TL, et al. Choosing antibiotics for intra-abdominal infections: What do we mean by "high risk"? Surg Infect 2009;10:29-39.
5. Sartelli M, Solomkin JS, Mazuski JE, et al. A focus on intra-abdominal infections: Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. World J Emerg Surg 2010;5:9.
6. Mazuski JE. Antimicrobial treatment for intra-abdominal infections. Expert Opin Pharmacother 2007;8:2933-2945. (Pubitemid 350285010)
7. Rybak MJ. Pharmacodynamics: Relation to antimicrobial resistance. Am J Infect Control 2006;34:S38-S45. (Pubitemid 43928178)
8. Goldberg J, Owens RC Jr. Optimizing antimicrobial dosing in the critically ill patient. Curr Opin Crit Care 2002;8:435-440.
9. Roberts JA, Ulldemolins M, Roberts MS, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: Proof of concept. Int J Antimicrob Agents 2010;36:332-339.
10. Roberts JA, Paratz J, Paratz E, et al. Continuous infusion of beta-lactam antibiotics in severe infections: A review of its role. Int J Antimicrob Agents 2007;30:11-18. (Pubitemid 46874893)
11. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: Focus on beta-lactam antibiotics: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006;26: 1320-1332. (Pubitemid 44306892)
12. Pea F, Viale P. Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock-Does the dose matter? Crit Care 2009;13:214.
13. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009;37:840-851.
14. Wittman DH, Schassan HH. Penetration of eight beta-lactam antibiotics into the peritoneal fluid: A pharmacokinetic investigation. Arch Surg 1983;118:205-213. (Pubitemid 13181578)
15. Bedikian A, Okamoto MP, Nakahiro RK, et al. Pharmaco-kinetics of meropenem in patients with intra-abdominal infections. Antimicrob Agents Chemother 1994;38:151-154. (Pubitemid 24018175)
16. Karjagin J, Lefeuvre S, Oselin K, et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther 2008;83:452-459. (Pubitemid 351272634)
17. Nilsson-Ehle I, Hutchison M, Haworth SJ, Norrby SR. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Eur J Clin Microbiol Infect Dis 1991;10:85-88.
18. Ikawa K, Morikawa N, Sakamoto K, et al. Pharmacokinetics and pharmacodynamic assessment of imipenem in the in-traperitoneal fluid of abdominal surgery patients. Chemotherapy 2008;54:131-139. (Pubitemid 351448600)
19. Ikawa K, Morikawa N, Urakawa N, et al. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients. J Antimicrob Chemother 2007;60: 1395-1397. (Pubitemid 350168341)
20. Cirillo I, Vaccaro N, Turner K, et al. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. J Clin Pharmacol 2009;49:798-806.
21. Ikawa K, Morikawa N, Ikeda K, et al. Pharmacodynamic evaluation of biapenem in peritoneal fluid using population pharmacokinetic modelling and Monte Carlo simulation. Int J Antimicrob Agents 2008;32:339-343.
22. Arrigucci S, Garcea A, Fallani S, et al. Ertapenem peritoneal fluid concentrations in adult surgical patients. Int J Anti-microb Agents 2009;33:371-373.
23. Majumdar AK, Musson DG, Birk KL, et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002;46:3506-3511. (Pubitemid 35192918)
24. Li C, Kuti JL, Nightingale CH, et al. Population pharmaco-kinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005;56:388-395. (Pubitemid 41158530)
25. Sörgel F, Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 1993;31(Suppl A):39-60. (Pubitemid 23078096)
26. Bujik SL, Gyssens IC, Mouton JW, et al. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother 2002;49:121-128. (Pubitemid 34100654)
27. Heim-Duthoy KL, Bubrick MP, Cocchetto DM, Matzke GR. Disposition of ceftazidime in surgical patients with intra-abdominal infection. Antimicrob Agents Chemother 1988;32: 1845-1847.
28. Sommers DK, Walters L, Van Wyk M, et al. Pharmacoki-netics of ceftazidime in male and female volunteers. Anti-microb Agents Chemother 1983;23:892-896. (Pubitemid 13104027)
29. Schwartz JI, Jauregui LE, Bachman KA, et al. Multiple dose pharmacokinetics of intravenously administered cefoper-azone and sulbactam when given in combination to infected, seriously ill, elderly patients. Antimicrob Agents Chemother 1988;730-735.
30. Meyers BR, Mendelson MH, Deeter RG, et al. Pharmacoki-netics of cefoperazone in ambulatory elderly volunteers compared with young adults. Antimicrob Agents Che-mother 1987;31:925-929. (Pubitemid 17084053)
31. Higuchi K, Ikawa K, Ikeda K, et al. Peritoneal pharmacoki-netics of cefepime in laparotomy patients with inflammatory bowel disease, and dosage considerations for surgical intra-abdominal infections based on pharmacodynamic assessment. J Infect Chemother 2008;14:110-116. (Pubitemid 351624459)
32. Ikawa K, Morikawa N, Matsuda S, et al. Peritoneal penetration and pharmacodynamic exposure of intravenous ce-fozopran in abdominal surgery patients. Int J Antimicrob Agents 2007;30:352-355. (Pubitemid 47361719)
33. Ikawa K, Morikawa N, Fukuhara K, et al. Penetration and exposure of cefotiam into the peritoneal fluid of abdominal surgery patients after intravenous administration. J Che-mother 2008;20:319-323. (Pubitemid 351998892)
34. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12. (Pubitemid 28068148)
35. Polk R. Optimal use of modern antibiotics: Emerging trends. Clin Infect Dis 1999;29:264-274. (Pubitemid 29380181)
36. Mouton JW, den Hollander JG. Killing of Pseudomonas aer-uginosa during continuous and intermittent infusion of cef-tazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994;38:931-936. (Pubitemid 24150817)
37. Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 2005;65:1611-1620. (Pubitemid 41138984)
38. Waibel BH, Rotondo MF. Damage control in trauma and abdominal sepsis. Crit Care Med 2010;38:S421-S430.
39. Marshall JC. Intra-abdominal infections. Microbes Infect 2004;6:1015-1025. (Pubitemid 39166044)
40. Ryan DM. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother 1993;31(Suppl D):1-16. (Pubitemid 23193749)
41. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
42. Gous A, Lipman J, Scribante J, et al. Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. Int J Antimicrob Agents 2005;26:50-55. (Pubitemid 40854116)
43. Sirinek KR. Diagnosis and treatment of intra-abdominal abscesses. Surg Infect 2000;1:31-38.
44. Galandiuk S, Appel SH, Polk HC Jr. A biologic basis for altered host defenses in surgically infected abscesses. Ann Surg 1993;217:624-632.
45. Xiong YQ, Caillon J, Drugeon H, et al. Influence of pH on adaptive resistance of Pseudomonas aeruginosa to aminogly-cosides and their postantibiotic effects. Antimicrob Agents Chemother 1996;40:35-39. (Pubitemid 26019674)
46. Kumar RR, Kim JT, Haukoos JS, et al. Factors affecting the successful management of intra-abdominal abscesses with antibiotics and the need for percutaneous drainage. Dis Colon Rectum 2006;49:183-189. (Pubitemid 43219953)
47. Chen H, Li F, Sun JB, Jia JG. Abdominal compartment syndrome in patients with severe acute pancreatitis in early stage. World J Gastroenterol 2008;14:3541-3548.
48. Schwarte LA, Scheeren TW, Lorenz C, et al. Moderate increase in intraabdominal pressure attenuates gastric mucosal oxygen saturation in patients undergoing laparoscopy. An-esthesiology 2004;100:1081-1087. (Pubitemid 38541962)
49. Mufarrej FA, Abell LM, Chawla LS. Understanding intra-abdominal hypertension: From the bench to the bedside. J Intensive Care Med 2011; e-pub Apr 27.
50. Ulldemolins M, Roberts JA, Lipman J, Rello J. Antibiotic dosing in multiple organ dysfunction syndrome. Chest 2011;139:1210-1220.
51. Varghese JM, Roberts JA, Lipman J. Antimicrobial pharma-cokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin 2011;27:19-34.
52. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: A review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005;44:1009-1034. (Pubitemid 41356389)
53. Drusano GL, Standiford HC, Bustamante CI, et al. The plasma pharmacokinetics of high dose (1g) imipenem coadministered with 1 g cilastatin in six normal volunteers. Eur J Clin Microbiol 1984;3:468-470. (Pubitemid 15203262)
54. Schwartz JI, Jauregui LE, Bachmann KA, et al. Multiple-dose pharmacokinetics of intravenously administered cefoper-azone and sulbactam when given in combination to infected, seriously ill, elderly patients. Antimicrob Agents Chemother 1988;32:730-735.
55. Barbhaiya RH, Forgue ST, Gleason CR, et al. Pharmacoki-netics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother 1992;36:552-557.
56. Lipman J. Towards better ICU antibiotic dosing. Crit Care Resusc 2000;2:282-289.
57. Roberts JA, Lipman J. Optimizing use of beta-lactam antibiotics in the critically ill. Semin Respir Crit Care Med 2007;28:579-585.
58. Scaglione F, Paraboni L. Pharmacokinetics/pharmacody-namics of antibacterials in the intensive care unit: Setting appropriate dosing regimens. Int J Antimicrob Agents 2008;32:294-301.
59. Soy D, Torres A. Antibacterial dosage in intensive-care-unit patients based on pharmacokinetic/pharmacodynamic principles. Curr Opin Crit Care 2006;12:477-482. (Pubitemid 44341716)
60. Roberts JA, Taccone FS, Udy AA, et al. Vancomycin dosing in critically ill patients: Robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 2011;55:2704-2709.
61. Roberts J. Importance of antibiotic dosing in critically ill patients. Curr Pharm Biotechnol 2011; e-pub May 10.
62. Ulldemolins M, Roberts JA, Rello J, et al. The effects of hy-poalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011;50:99-110.
63. Udy AA, Putt MT, Shanmugathasan S, et al. Augmented renal clearance in the intensive care unit: An illustrative case series. Int J Antimicrob Agents 2010;35:606-608.
64. Martin JH, Fay MF, Udy A, et al. Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Int Med J 2010;40:395-398.
65. Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: Implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010;49:1-16.
66. Ulldemolins M, Roberts JA, Wallis SC, et al. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: Special emphasis on unbound pharmacokinetics. J Anti-microb Chemother 2010;65:1771-1778.